• H.E. Dr. Bandar Alknawy, CEO-MNGHA, KSAU-HS President
• Dr. Ahmed Alaskar, KAIMRC Executive Director
• Dr. Mohamed Boudjelal, Conference Chairman
The Innovations from the COVID Pandemic That Will Make the Biggest Impact on Health by 2030 (30 min)
Dr. Ashley McKimm,
Editor-in-Chief, BMJ Innovations
Academic Drug Discovery in Practice – Learnings from the national Swedish SciLifeLab endeavourer with a twist towards targeted protein degradation (30 min)
Prof. Per I. Arvidsson,
Executive Director Drug Discovery & Development
Science for Life Laboratory Stockholm, Sweden
Chairperson: Dr. Majed Al Ghoribi, Infectious Diseases Department Chairman, KAIMRC
FIGHTING INFECTIOUS DISEASES AND TOXINS WITH RECOMBINANT ANTIBODIES (20 min)
Prof. Dr. Michael Hust, Technische Universität Braunschweig, Germany
Vaccines and therapies based on synthetic mRNA (20 min)
Dr. Steve Pascolo, Founder And CEO, Miescher Pharma GmbH, Zurich, Switzerland
Leukotriene inhibitors as promising treatment for COVID-19: a New Drug Discovery made in KSA (15 min)
Prof. Mohammed Al Ghobain, Consultant Pulmonologist at King Abdulaziz Medical City, Riyadh, KSA
Cnicin as an Anti-SARS-CoV-2: An Integrated in Silico and in Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics” (15 min)
Dr. Hani Abdullah Alhadrami, Consultant, King Abdulaziz University Hospital. King Fahad Medical Research Center, Jeddah, KSA.
Discussion (20 min)
Chairperson: Dr. Bader Alahmari, Chairman, Department of Blood and Cancer Research
Pathogenic Inflammation in COVID 19 (20 min)
Prof. Miriam Merad, Director of the Precision Immunology Institute at Mount Sinai School of Medicine, New York, USA
Anti-SARS-CoV-2 drug discovery: from drug repurposing to traditional Chinese medicine (20 min)
Prof. Hang Yang, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
From COVID-19 vaccines to broader therapeutics based on mRNA-encoded proteins (20 min)
Dr. Cesar Sanz Rodriguez, Vice President Medical Affairs – Europe, Middle East & Africa
Discussion 20 min
Chairperson: Dr. Bader Muzaini, Deputy Chairman, Genetic Department, KAIMRC
Genetic and Rare disease program (GARD): an opportunity for orphan diseases drug discovery and development (20 min)
Prof. Majid Alfadhel, Deputy Executive Director, Chairman, Genetics and Precision Medicine Department, King Abdulaziz Medical City, Riyadh, KSA
Rare Diseases Genetic Link (20 min)
Prof. Fowzan S Alkuraya, MD Principal Clinical Scientist and Senior Consultant, Chairman, Translational Genomics (Center for Genomic Medicine), King Faisal Specialist Hospital and Research Center, Riyadh, USA
Discussion 20 min
Chairperson: Dr. Zeyad Al Ehaideb, Team Leader Medicinal Plant, KAIMRC / Dr. Sameer Mohammad Senior Scientist KAIMRC
Investigating the role of ONECUT2 in brain tumour (10 min)
Ms. Rania Ahmed Haddadi,
Supervisor: Dr. Bahauddeen ALRfaei, Cellular Therapy and Cancer Research, KAIMRC
Functional significance of RNA binding proteins (RBPs) in Adipose biology (10 min)
Ms. Ghida Dairi
Supervisor: Dr. Sameer Mohammad, Experimental Medicine, KAIMRC
Hsp70 family interplay during heat-induced proteotoxic stress in modular neuronal cells (10 min)
Ms. Tahani Hassan Asiri
Supervisor: Dr. Shuja Malik, Experimental Medicine, KAIMRC
Commiphora myrrha constituents induce cytochrome P-450 enzyme metabolic enzymes in HepG2 cells: in vitro and in silico studies (10 min)
Ms. Amani Al-Sharidah
Supervisor: Dr. Zeyad Al Ehaideb, Natural Medicine, KAIMRC
Isolation, establishment, and characterization of natural and induced immortalized cancer cell lines from Saudi cancer patients (10 min)
Ms. Saba AL Subaie
Supervisor: Dr. rer. nat. Rizwan Ali, Team Leader of Light and Electron Microscopy Unit, KAIMRC
Chairperson: Dr. Fayhan Rogi , Immunotherapy Department Head, KAIMRC, Dr. Tlili Barhoumi, Cell-Flow Cytometry Platform, KAIMRC, KSA
BREAST CANCER IN DIABETES – DO ANTIGLYCATION COMPOUNDS HAVE A ROLE? (20 min)
Prof. Nessar Ahmed CSci FIBMS
Reader in Clinical Biochemistry, Department of Life Sciences, Manchester Metropolitan University, UK
Considerations for monoclonal antibody development by phage display (20 min)
Dr. Lim Theam Soon
Associate Professor at Universiti Sains Malaysia
Molecular/Precision Oncology Tumor Boards; NGHA local experience (15 min)
Dr. Kanan Alshammari
Director, Middle East – North Africa National Comprehensive Cancer Network (MENA NCCN) Coordinating Center King Abdulaziz Medical City, MNGHA
Identification of Neoantigens from Breast Tumor as Targets for Immunotherapy (15 min)
Dr. Mamoon Rashid
Department of AI and Bioinformatics
King Abdullah International Medical Research Center (KAIMRC)
Discussion 20 min
Chairperson: Dr. Imadul Islam, Senior Research Scientist-Deputy Director Drug Discovery Program, KAIMRC / Dr. Bandar Alghanem, Head of Proteomics and Metabolomics, KAIMRC
The Fraunhofer 4 D concept for Health: combining drugs, device, diagnostics with data: how we can improve drug discovery to the benefit of the patients (20 min)
Prof. Dr. Claussen, Carsten
Director Fraunhofer IME ScreeningPort, Hamburg, Head of Fraunhofer “Initiative Medical Data Space”, Germany
Targeting cellular senescence to extend healthspan and resilience (20 min)
Paul D. Robbins Institute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN
Novel CAR-T cell Therapy Development and Mechanistic Studies. (20 min)
Prof. Peng li,
Principal Investigator, Guangzhou Institutes of Biomedicine and Health, CAS (Guangzhou, China)
Recent Trends on How to Overcome Multidrug Resistant Bacterial Infections’ (15 min)
Dr. Essam A. Tawfik; Director of the National Center for Pharmaceutical Technology at King Abdulaziz City for Science and Technology (KACST) Saudi Arabia
KAIMRC’S Discoveries of For MERS-CoV and SARS-CoV2 Inhibitors (15 min)
Dr. Nimer Mehyar, Head Protein-Enzymology Unit, KAIMRC-KSAU Researcher, KSA
Discussion 30 min
Chairperson: Dr. Bahauddeen ALRfaei , Cellular Therapy and Cancer Research, KAIMRC
PINK1 has a major role in the survival of Medulloblastoma cells
(10 min)
Ms Aliya Nashmi
Mentor: Dr. Bahauddeen ALRfaei , KAIMRC
Effect of Environmental Factors on Monkeypox Cellular Infection (10 min)
Ms Ghada Alqarni
Mentor: Dr. Naif Alharbi , Ex-KAIMRC
Peroxisome Proliferator Activated Receptor α modulators as potential cancer therapy (10 min)
Ms Raghd AlGhamdi
Mentor: Dr. Arwa Alsuabit, KAIMRC
Functional study of RYR3 gene function using CRISPR system (10 min)
MS Jory Al Salamah
Mentor: Dr. Bader Muzaini, KAIMRC
Identification of a Rare Variant Associated with Congenital Heart Defect in a Saudi Family (10 min)
Ms. Layan Almojel
Mentor: Dr. Manal Alaamry, KAIMRC
Chairperson: Dr. Lamya Omair, Head of AI and Bioinformatics Department, KAIMRC
End-to-end AI drug discovery for kick-starting novel therapeutic programs (20 min)
Dr. Alex Zhavoronkov
Founder and CEO of Insilico Medicine (insilico.com)
Machine Learning Applications in Deconvoluting Hit Molecules into Fragments (20 min)
Dr. Shahul Nilar
Director, Computational Chemistry at Global Blood Therapeutics South San Francisco, USA
AI for in silico clinical trials and precision medicine. (20 min)
Dr. James Zou; Biomedical data science, CS and EE at Stanford University, USA
Dr. Ryan Copping ; Global Head of Data Science Acceleration (DSX); PD Data Sciences, Product Development (PD) Roche & Genentech, USA
Unlocking the protein universe to discover the medicines of tomorrow (20 min)
Dr.Naheed Kurji Co-founder, President & CEO;Cyclica Inc.
Discussion 10 min
Chairperson: Dr. Barrak Al Somaie, Director of Operation and Member of KAIMRC Funding Committee, KAIMRC, KSA
Clinical evaluation of new medicines in a regulatory setting (15 min)
Dr. Ahmed Alkhaldi , Head of clinical studies at the Saudi Food and Drug Authority, Riyadh, KSA
Determining drug profiles to improve clinical trial outputs.
Sheraz Gul, Fraunhofer IME ScreeningPort, Hamburg
KAIMRC Clinical Trial Setting (15 min)
Dr. Mohammad Bosaeed,, Infectious Disease Consultant, Department of Medicine, King Abdulaziz Medical city, Riyadh, KSA
Discussion 15 min
Chairperson: Dr. Majid Aljeraisy, Chairman, Research Office and Director, Clinical Trial Services
Prof. Dr. Claussen, Carsten
Director Fraunhofer IME ScreeningPort, Hamburg, Head of Fraunhofer “Initiative Medical Data Space”, Germany
Dr. Mohammad Bosaeed,, Infectious Disease Consultant, Department of Medicine, King Abdulaziz Medical city, Riyadh, KSA
Dr.Naheed Kurji Co-founder, President & CEO;Cyclica Inc.
Dr. Alex Zhavoronkov Founder and CEO of Insilico Medicine (insilico.com)
Dr. Shahul Nilar
Director, Computational Chemistry at Global Blood Therapeutics
South San Francisco, USA
Dr. Ahmed Alkhaldi (15 min)
Head of clinical studies at the Saudi Food and Drug Authority, Riyadh, KSA